AZN Astrazeneca plc

Price (delayed)

$78.135

Market cap

$242.24B

P/E Ratio

38.11

Dividend/share

$1.45

EPS

$2.05

Enterprise value

$268.95B

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Highlights
AZN's net income is up by 35% year-on-year and by 6% since the previous quarter
Astrazeneca's EPS has increased by 35% YoY and by 7% QoQ
AZN's price to earnings (P/E) is 72% lower than its 5-year quarterly average of 138.9 but 11% higher than its last 4 quarters average of 34.9
AZN's equity is up by 4.6% year-on-year but it is down by 4.3% since the previous quarter
AZN's debt is up by 21% since the previous quarter and by 10% year-on-year

Key stats

What are the main financial stats of AZN
Market
Shares outstanding
3.1B
Market cap
$242.24B
Enterprise value
$268.95B
Valuations
Price to book (P/B)
6.47
Price to sales (P/S)
5.08
EV/EBIT
29.54
EV/EBITDA
18.88
EV/Sales
5.65
Earnings
Revenue
$47.61B
EBIT
$9.11B
EBITDA
$14.25B
Free cash flow
$8.23B
Per share
EPS
$2.05
Free cash flow per share
$2.66
Book value per share
$12.08
Revenue per share
$15.37
TBVPS
$14.04
Balance sheet
Total assets
$102.29B
Total liabilities
$64.79B
Debt
$34.55B
Equity
$37.45B
Working capital
-$3.31B
Liquidity
Debt to equity
0.92
Current ratio
0.89
Quick ratio
0.69
Net debt/EBITDA
1.88
Margins
EBITDA margin
29.9%
Gross margin
82%
Net margin
13.3%
Operating margin
18.4%
Efficiency
Return on assets
6.4%
Return on equity
16.8%
Return on invested capital
24.9%
Return on capital employed
12.4%
Return on sales
19.1%
Dividend
Dividend yield
1.86%
DPS
$1.45
Payout ratio
70.7%

AZN stock price

How has the Astrazeneca stock price performed over time
Intraday
-1.39%
1 week
1.3%
1 month
-1.83%
1 year
15.96%
YTD
16.01%
QTD
0.19%

Financial performance

How have Astrazeneca's revenue and profit performed over time
Revenue
$47.61B
Gross profit
$39.03B
Operating income
$8.76B
Net income
$6.33B
Gross margin
82%
Net margin
13.3%
AZN's operating income has surged by 61% year-on-year and by 7% since the previous quarter
The operating margin has grown by 48% YoY and by 2.8% from the previous quarter
AZN's net income is up by 35% year-on-year and by 6% since the previous quarter
AZN's net margin is up by 24% year-on-year and by 2.3% since the previous quarter

Growth

What is Astrazeneca's growth rate over time

Valuation

What is Astrazeneca stock price valuation
P/E
38.11
P/B
6.47
P/S
5.08
EV/EBIT
29.54
EV/EBITDA
18.88
EV/Sales
5.65
AZN's price to earnings (P/E) is 72% lower than its 5-year quarterly average of 138.9 but 11% higher than its last 4 quarters average of 34.9
Astrazeneca's EPS has increased by 35% YoY and by 7% QoQ
The stock's price to book (P/B) is 17% more than its last 4 quarters average of 5.6 but 10% less than its 5-year quarterly average of 7.3
AZN's equity is up by 4.6% year-on-year but it is down by 4.3% since the previous quarter
The stock's price to sales (P/S) is 10% more than its last 4 quarters average of 4.7 and 5% more than its 5-year quarterly average of 4.9
Astrazeneca's revenue has increased by 9% YoY and by 3.9% QoQ

Efficiency

How efficient is Astrazeneca business performance
Astrazeneca's return on invested capital has surged by 64% YoY and by 4.2% QoQ
Astrazeneca's return on sales has surged by 50% YoY and by 2.7% QoQ
The return on assets is up by 31% year-on-year and by 4.9% since the previous quarter
The company's return on equity rose by 28% YoY and by 6% QoQ

Dividends

What is AZN's dividend history
DPS
$1.45
Dividend yield
1.86%
Payout ratio
70.7%
Recent dividends

Financial health

How did Astrazeneca financials performed over time
The company's total assets is 58% higher than its total liabilities
The quick ratio rose by 11% since the previous quarter
AZN's current ratio is up by 9% from the previous quarter
AZN's debt is 8% smaller than its equity
AZN's debt to equity is up by 26% since the previous quarter and by 4.5% year-on-year
AZN's debt is up by 21% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.